The relationship between the use of mTORinhibitors and COVID-19 outcomes in kidney transplant recipients has been studied in a growing body of literature [8].However, there isn't much agreement on the overall impact of mTOR inhibitors in this particular patient population because individualstudies frequently report conflicting results [9]. This evidence concerns the gene MTOR and COVID-19.